Bibliografia

1. Epidemiologia - Prof. Roberto Miano

1. Shoag J, Tasian GE, Goldfarb DS, Eisner BH. The new epidemiology of nephrolithiasis. Adv Chronic Kidney Dis. 2015 Jul;22(4):273-8.

2. Scales CD Jr, Tasian GE, Schwaderer AL, Goldfarb DS, Star RA, Kirkali Z. Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1305-12.

3. Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project.. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-5.

4. Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. 1999 Jul;162(1):27-30.

5. West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994.

2. Elementi di fisiopatologia - La Litogenesi – Dr. Martino MARANGELLA

1. Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BE. Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med. 1976; 294:249-52

2. Nicar HK, Pak CYC. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism 1983; 332:906-10.

3. Coe FL, Parks JH, Nakagawa Y. Inhibitors and promoters of calcium oxalate crystallization: Their relationship to the pathogenesis and treatment of nephrolithiasis, in Disorders of Bone and Mineral Metabolism, edited by Coe FL and Favus MJ. New York, Raven Press, 1992, p 757.

4. Kok DJ, Papapoulos SE, and Bijvoet OLM. Excessive crystal agglomeration with low citrate excretion in recurrent stone formers. Lancet 1986; i: 1056–1058.

5. Marangella M, Petrarulo M, Daniele PG, Sammartano S. LithoRisk: A software for calculating and visualising nephrolithiasis risk profiles. G Ital Nefrol. 2002;19:693.

3. Elementi di fisiopatologia - METABOLISMO CALCIO FOSFORO
Prof. Piergiorgio MESSA

1. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1257-72.

2. Lambers TT, Bindels RJ, Hoenderop JG: Coordinated control of renal Ca21 handling. Kidney Int 69: 650–654, 2006.

3. Marks J, DebnamES, Unwin RJ: Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 299: F285–F296, 2010.

4. Biber J, Hernando N, Forster I, Murer H: Regulation of phosphate transport in proximal tubules. Pflugers Arch 458: 39–52, 2009.

4. Elementi di fisiopatologia - L'equilibrio acido-base - Dr. Corrado VITALE

1. Hamm LL, Nakhoul N and Hering-Smith KS. Acid-Base homeostasis. Clin J Am Soc Nephrol 2015; 10: 2232–42.

2. Brown D and Wagner CA. Molecular mechanisms of acid-base sensing by the kidney. J Am Soc Nephrol 2012; 23: 774–80.

3. BatlleD and Haque SK. Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol Dial Transplant 2012; 27: 3691–704.

4. Adrogue HJ, Gennari FJ, Galla JH and Madias NE. Assessing acid–base disorders. Kidney International 2009; 76 (12), 1239–47.

5. Lemann J Jr., Bushinsky DA and Hamm LL. Bone buffering of acid and base in humans. Am J Physiol Renal Physiol 2003; 285: F811–F832.

5. Metabolismo ed handling renale di Ossalato e Citrato - Dr. Martino MARANGELLA

1. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369:649-58.

2. Marangella M, Petrarulo M, Bermond F, Marcuccio C, Vitale C. The Hyperoxalurias. G Ital Nefrol. 2016 Malattie Metaboliche e Rene;33(S68).

3. Holmes RP, Assimos DG. The impact of dietary oxalate on kidney stone formation. Urol Res. 2004;32:311-6.

4. Simpson DP. Citrate excretion: a window on renal metabolism. Am J Physiol. 1983;244:F223-34.

6. Uricosuria e calcolosi renale – Dr. Alberto TRINCHIERI

1. Gutman AB, Yu TF. Uric acid nephrolithiasis. Am J Med. 1968;45:756–779.

2. Ngo TC, Assimos DG Uric acid nephrolithiasis: recent progress and future directions Rev Urol. 2007 Winter; 9(1): 17–27.

3. Sakhaee K Epidemiology and clinical pathophysiology of uric acid kidney stones J Nephrol. 2014 Jun; 27(3): 241–245.

7. Sindrome metabolica e nefrolitiasi calcica – Prof. Pasquale STRAZZULLO

1. Rendina D, De Filippo G, D'Elia L, Strazzullo P. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J Nephrol. 2014 ;27:371-6.

2. Rendina D, De Filippo G, Zampa G, Muscariello R, Mossetti G, Strazzullo P. Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome. Nephrol Dial Transplant. 2011;26:2256-63

3. Li H, Klett DE, Littleton R, Elder JS, Sammon JD. Role of insulin resistance in uric acid nephrolithiasis. World J Nephrol. 2014,3:237-42

4. Tran TY, Flynn M, O'Bell J, Pareek G. Calculated insulin resistance correlates with stone-forming urinary metabolic changes and greater stone burden in high-risk stone patients. Clin Nephrol. 2016;85:316-20.

8. Iperparatiroidismo e Nefrolitiasi – Prof. Giovanni GAMBARO

1. Vestergaard P. Primary hyperparathyroidism and nephrolithiasis. Ann Endocrinol (Paris). 2015 May;76(2):116-9. doi: 10.1016/j.ando.2015.03.002. Review.

2. Crowley RK, Gittoes NJ. When would I use medical therapies for the treatment of primary hyperparathyroidism? Clin Endocrinol (Oxf). 2013 Dec;79(6):770-3. doi: 10.1111/cen.12344.

3. Felsenfeld AJ, Levine BS, Kleeman CR. Fuller Albright and our current understanding of calcium and phosphorus regulation and primary hyperparathyroidism. Nefrologia. 2011;31(3):346-57. doi: 10.3265/Nefrologia.pre2011.Mar.10774. Review.

9. Calcolosi e metabolismo osseo - Dr. Corrado VITALE

1. Taylor EN, Feskanich D, Paik JM and Curhan GC. Nephrolithiasis and risk of incident bone fracture. J Urol 2016; 18,195(5):1482-6.

2. Krieger NS and Bushinsky DA. The relation between bone and stone formation. Calcif Tissue Int. 2013; 93(4): 374–81.

3. Letavernier E, Traxer O, Daudon M, Tligui M, Hubert-Brierre J, Guerrot D, Sebag A, Baud L and Haymann JP. Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria. Clin J Am Soc Nephrol 2011; 6: 1149–54.

4. Sakhaee K, Maalouf NM, Kumar R, Pasch A and Moe OW. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 2011; 79:393–403.

5. Asplin JR, Bauer KA, Kinder J, Muller G, Coe BJ, Parks JH and Coe FL. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int. 2003; 63:662–9.

10. La calcolosi renale nelle sindromi da malassorbimento – Dr. Corrado VITALE

1. Marangella M, Petrarulo M, Bermond F, Marcuccio C and Vitale C: The hyperoxalurias. G Ital Nefrol. 2016; Malattie Metaboliche e Rene; 33 (S68).

2. Nazzal L, Puri S and Goldfarb DS. Enteric hyperoxaluria: an important cause of end-stage kidney disease. Nephrol Dial Transplant 2016; 31(3):375-82.

3. Asplin JR. The management of patients with enteric hyperoxaluria. Urolithiasis 2016; 44(1):33-43.

4. Bhatti UH, Duffy AJ, Roberts KE and Shariff AH. Nephrolithiasis after bariatric surgery: a review of pathophysiologic mechanisms and procedural risk. Int J Surg. 2016; 36:618-23.

5. Sakhaee K, Poindexter J and Aguirre C. The effects of bariatric surgery on bone and nephrolithiasis. Bone 2016; 84: 1–8.

11. Le forme ereditarie di Nefrolitiasi: quando sospettarle – Prof. Giovanni GAMBARO

1. Mohebbi N, Ferraro PM, Gambaro G, Unwin R. Tubular and genetic disorders associated with kidney stones. Urolithiasis. 2017 Feb;45(1):127-137. doi: 10.1007/s00240-016-0945-y. Review.

2. Ferraro PM, D'Addessi A, Gambaro G. When to suspect a genetic disorder in a patient with renal stones, and why. Nephrol Dial Transplant. 2013 Apr;28(4):811-20. doi: 10.1093/ndt/gfs545. Review.

3. Vezzoli G, Terranegra A, Arcidiacono T, Soldati L. Genetics and calcium nephrolithiasis. Kidney Int. 2011 Sep;80(6):587-93. doi: 10.1038/ki.2010.430. Review.

4. Gambaro G, Vezzoli G, Casari G, Rampoldi L, D'Angelo A, Borghi L. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis. 2004 Dec;44(6):963-86. Review.

12. Prevenzione e Terapia Nutrizionale della nefrolitiasi Calcica
Prof. Pasquale STRAZZULLO

1. Gambaro G, Croppi E, Coe F et al. Consensus Conference Group. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016;29:715-34.

2. Prezioso D, Strazzullo P, Lotti T et al. CLU Working Group. Dietary treatment of urinary risk factors for renal stone formation. A review of the CLU Working Group. Arch Ital Urol Androl. 2015;87:105-20.

3. Taylor EN and Curhan GC. Determinants of 24-hour urinary oxalate excretion. Clin J Am Soc Nephrol 2008;3:1453–60.

4. Borghi L, Schianchi T, Meschi T et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84

5. Lemann J Jr, Bushinsky DA, Hamm LL. Bone buffering of acid and base in humans. Am J Physiol Renal Physiol. 2003;285:F811-32.

6. Taylor EN1, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009;20:2253-9.

13. Terapia medica e Profilassi della calcolosi renale – Dr. Martino MARANGELLA

1. Pak CYC. Citrate and renal calculi: an update. Miner Electrolyte Metab. 1994; 20: 371–7

2. Escribano J, Balaguer A, Pagone F, Feliu A, Roqué I Figuls M. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database Syst Rev. 2009;21:CD004754

3. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363:954-63.

4. Coe FL, Evan A, Worcester E. Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol. 2011;6:2083-92.

5. Phillips R, Hanchanale VS, Myatt A, Somani B, Nabi G, Biyani CS. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015;10: CD010057.

6. Marangella M. Medical management of urinary calculi: up to date 2016. Urologia. 2016;83:110-23.

7. Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int. 2004;72 Suppl 1:6-10.

8. De Yoreo JJ, Qiu SR, Hoyer JR. Molecular modulation of calcium oxalate crystallization. Am J Physiol Renal Physiol. 2006;291:F1123-31.

14. Trattamento chirurgico calcolosi reno-ureterale – Dr. Alberto TRINCHIERI

1. Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, Pace KT, Pais VM Jr, Pearle MS, Preminger GM, Razvi H, Shah O, Matlaga BR. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART I. J Urol. 2016 Oct;196(4):1153-60.

2. Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T.EAU Guidelines on Interventional Treatment for Urolithiasis. Eur Urol. 2016 Mar;69(3):475-82.

3. Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck AC, Gallucci M, Knoll T, Lingeman JE, Nakada SY, Pearle MS, Sarica K, Türk C, Wolf JS Jr; American Urological Association Education and Research, Inc.; European Association of Urology.. 2007 Guideline for the management of ureteral calculi. Eur Urol. 2007 Dec;52(6):1610-31.